Skip to Content
Søg Menu
9.-13. september 2022

Vi var på ESMO 2022 I European Society for Medical Oncology

Seneste fra ESMO 2022

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

  • / Eric Pujade-Lauraine

SABCS Kongresside

Her finder du abstracts, online artikler, MEDtalks med internationale og nationale key opinion leaders fra SABCS

Se mere

MCED blood test – a gamechanger for early cancer detection for cancer

/ Hæmatologi / BestPractice Nordic

Air pollution and lung cancer in never-smoking people 

/ Onkologi / BestPractice Nordic

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ Onkologi / BestPractice Nordic

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ Onkologi / BestPractice Nordic

A major threat to human health

/ Onkologi / BestPractice Nordic

MEDtalks fra ESMO 2022

Global consensus: Management of epithelioid hemangioendothelioma

/ Onkologi / Silvia Stacchiotti

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Onkologi / Eric Pujade-Lauraine

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Onkologi / Alan Celik

Opdatering på CheckMate 649-studiet

/ Onkologi / Lene Bæksgaard

High-risk factors in patients with advanced ovarian cancer impact survival

/ Onkologi / Dana Chase
Se oversigt

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

Tema: Lungecancer

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

  • / Siow Ming Lee

Can High-Intensity Aerobic exercise give patients with cancer better survival by stimulating the immune system?

/ Onkologi / Gitte Holmen Olofsson

Langtidsholdbar og robust overlevelsesdata for stadie IV-NSCLC – 3 års update fra CheckMate 9LA studiet

/ Onkologi / Edyta Maria Urbanska

Betydning af screening og selektering for overlevelsen ved lungecancer

/ Onkologi / Torben Riis Rasmussen

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

Klinik for senfølger efter kræft: 80% af de besøgende er kvinder

/ Almen praksis / Karin Brochsted Dieperink

Abstracts fra ESMO 2022

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynækologisk cancer

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

/ BestPractice Nordic
ESMO22Nyrecancer

ESMO 2022 –” Understanding the disease to provide better care for cancer patients”  

/ BestPractice Nordic
ESMO22
Hent flere

Faglig test – Pulmonalt planocellulært karcinom

Test din viden om pulmonalt planocellulært karcinom

Tag testen her

ESMO 2021

Ma Pilar Barretina-Ginesta

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Ma Pilar Barretina-Ginesta
ESMO21Gynækologisk cancer Play the Video
Roy S. Herbst

Klinisk perspektivering af COAST-studiet for patienter med metastatisk ikke-operable stadie III ikke-småcellet lungecancer

/ Roy S. Herbst
ESMO21Lungecancer Play the Video
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21Lungecancer Play the Video
Camillo Porta

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Camillo Porta
ESMO21Immunterapi Play the Video
Jared Weiss

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Jared Weiss
ESMO21Colorektalcancer Play the Video
Ahmet Sezer

Perspective of first line immune therapy of non-small-cell lung cancer

/ Ahmet Sezer
ESMO21Lungecancer Play the Video
Hent flere

Highlights fra ESMO 2021 (2:2)

/ Tine McCulloch / Weronika Szejniuk
ESMO21Lungecancer Play the Audio 13:00

ESMO 2021 – Highlights om lungecancer (1:2)

/ Tine McCulloch / Weronika Szejniuk
ESMO21Lungecancer Play the Audio 14:41

MEDtalks fra ESMO 2020

Sidsel Kølle Pedersen

Dansk real-life studie viser, at prognosen for malignt melanom med hjernemetastaser er forbedret siden 2015

/ Sidsel Pedersen
ESMO21HjernemetastaserMelanom Play the Video
Nir Peled

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Nir Peled
ESMO21Cancer Play the Video

Immunterapi har positiv effekt på ubehandlede hjernemetastaser ved ikke-småcellet lungecancer

/ Birgitte Bjørnhart
ESMO21HjernemetastaserLungecancer Play the Video

Dobbelt immunterapi giver fortsat bedre overlevelse ved malignt pleural mesotheliom

/ Jens Benn Sørensen
ESMO21Cancer Play the Video

Potential as new standard treatment of HER2+ metastatic breast cancer

/ Javier Cortés
ESMO21Brystcancer Play the Video

IL-6 receptor hæmmer dæmper bivirkninger ved immun checkpoint hæmmer behandling

/ Rikke Bødker Holmstrøm
ESMO21Immunterapi Play the Video
Se mere fra ESMO
Back to top